The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
May 13th 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
RET Joins the Ranks of Actionable Targets in Precision Oncology
February 1st 2021Over the past 2 decades, a growing number of targetable tumor-specific molecular alterations have been identified, ushering in the era of precision oncology. Now, alterations in the RET gene can be added to the list of druggable targets.
HRQoL Maintained With Adjuvant Osimertinib in EGFR+ NSCLC
January 30th 2021January 29, 2021 - Health-related quality of life was maintained for patients with EGFR-positive non–small cell lung cancer who received treatment with adjuvant osimertinib versus placebo, with no clinically meaningful differences noted between study arms.
Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC
January 30th 2021January 29, 2021 — Mobocertinib (formerly TAK-788) demonstrated clinically meaningful benefit and a manageable safety profile in previously treated patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations.
Sotorasib Elicits Rapid Responses, Encouraging PFS in Advanced KRAS G12C+ NSCLC
January 28, 2021 - Treatment with the KRAS G12C inhibitor sotorasib (formerly AMG 510) elicited a 6.8-month median progression-free survival in patients with KRAS G12C–mutated advanced non–small cell lung cancer.
NeoADAURA Trial Slated to Examine Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC
January 28th 2021January 28, 2021 - The NeoADAURA trial will evaluate the safety and efficacy of neoadjuvant osimertinib, as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone, in patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.
Osimertinib/Savolitinib Combo May Overcome MET Resistance in EGFR+, MET-Amplified NSCLC
January 28th 2021January 28, 2021 - The combination of osimertinib and savolitinib may be able to overcome MET resistance in patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer, including those who have previously progressed on a prior EGFR TKI.
Osimertinib Displays Uniform Brain Penetrance and Reduced Metastatic Volume in EGFR+ NSCLC
January 28th 2021January 28, 2021 - Rapid, high, and uniform brain exposure was seen with [11C]osimertinib, followed by a reduction in total brain metastases volume with oral administration of the EGFR TKI in patients with EGFR-mutant non–small cell lung cancer and brain metastases.
Real-World Study Confirms NRG1 Fusions in NSCLC, Supports Afatinib Studies
January 28, 2021 - NRG1 fusions are detectable in patients with non–small cell lung cancer, providing a rationale to perform larger, retrospective studies assessing therapeutic outcomes in patients with NRG1 fusion–positive tumors and evaluate afatinib in this patient subgroup.
Expert Panel Weighs Practice-Changing Potential of Early Data in EGFR+ NSCLC
As new findings emerge in the lung cancer treatment paradigm, innovative strategies have resulted in impressive central nervous system activity and encouraging responses with acceptable tolerability.
Real-World Data Grow Increasingly Relevant in Oncology Practice
January 27th 2021The importance of objectively valid data is well established in clinical medicine. Such data include an accurate recording of a patient’s clinical history; evaluation of signs and symptoms of illness; and measurement of various routine indicators, such as granulocyte and platelet counts, serum glucose, electrolytes, and liver function tests.
Durvalumab, Osimertinib Envelop Adjuvant and Neoadjuvant NSCLC Treatment
January 25th 2021The sustained overall survival benefit with durvalumab and significant disease-free survival benefit benefit with osimertinib in the adjuvant setting represent major advances in the field of non–small cell lung cancer, fueling research with each modality in localized settings.
HER2-Directed Antibody-Drug Conjugates May Carve Out a Place in NSCLC Landscape
January 21st 2021The current standard of care for patients with non–small cell lung cancer does not include therapies targeting HER2, a mutation that occurs in up to 4% of cases. However, data from recent studies of antibody-drug conjugates directed at HER2 activity are generating excitement about the potential utility of ADCs in this space.
New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward
January 20th 2021Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.
Could Orca-T Unlock New Path of Reduced Mortality, Prevent GVHD Posttransplant?
Steven Devine, MD, discusses the non-relapse mortality data with Orca-T and how this technologic approach is changing how providers approach patients with hematologic malignancies following transplant.
Frontline Bemarituzumab/mFOLFOX6 Combo Improves Survival in Advanced FGFR2b+ Gastric/GEJ Cancer
Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.
FDA Approves Crizotinib for Pediatric and Young Adult ALK+ Anaplastic Large Cell Lymphoma
January 14, 2021 - The FDA has approved crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large cell lymphoma.
Fleshing Out HER2-Directed Therapies in GI Malignancies
January 11th 2021The field of HER2-positive gastrointestinal malignancies witnessed a surge of data in 2020 regarding investigational agents, such as the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki, that could play a pivotal role in transforming treatment selection in the coming years.
Larotrectinib Elicits Durable Responses, Extends Survival in TRK+ Sarcomas
January 11, 2021 - Larotrectinib was found to induce a high response rate with long durability and improve survival in patients with TRK-positive sarcomas, according to results from an analysis of 3 clinical trials.
Osimertinib/Bevacizumab Improves ORR, But Fails to Prolong PFS in EGFR T790M+ NSCLC
January 8, 2021 — The combination of osimertinib plus bevacizumab failed to result in a statistically significant improvement in progression-free survival versus osimertinib alone in patients with advanced lung adenocarcinoma that harbored an EGFR T790M mutation.
FDA Grants Fast Track Designation to Zenocutuzumab for Metastatic NRG1+ Solid Tumors
January 8, 2021 — The FDA has granted a fast track designation to zenocutuzumab for the treatment of patients with metastatic solid tumors that harbor NRG1 gene fusions and have progressed on standard-of-care treatment.
Approval for Amivantamab Sought in Europe for Metastatic EGFR Exon 20+ NSCLC
January 4th, 2021 - A marketing authorization application has been submitted to the European Medicines Agency for the approval of amivantamab as a treatment for patients with metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations who have experienced disease progression following platinum-based chemotherapy.
EU Approval Sought for Sotorasib in KRAS G12C–Mutated Advanced or Metastatic NSCLC
January 4, 2021 - A marketing authorization application has been submitted to the European Medicines Agency for the use of sotorasib in patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer.